$ADMA
ADMA BIOLOGICS, INC. Stock $adma

$adma Overview Financials Valuation SEC Filings Company Website

2020 Q3 Form 10-Q Financial Statement

#000119380520000960 Filed on August 05, 2020

Income Statement

Concept	2020 Q3	2020 Q2	2019 Q2
Revenue	$10.28M	$7.788M	$6.561M
YoY Change	42.28%	18.7%	40.79%
Cost Of Revenue	$11.86M	$13.50M	$10.49M
YoY Change	49.76%	28.64%	8.72%
Gross Profit	-$1.579M	-$5.708M	-$3.930M
YoY Change	127.63%	45.23%	-21.24%
Gross Profit Margin	-15.37%	-73.3%	-59.9%
Selling, General & Admin	$10.33M	$9.580M	$6.680M
YoY Change	35.03%	43.41%	-0.89%
% of Gross Profit
Research & Development	$1.708M	$1.656M	$2.000M
YoY Change	247.66%	-17.18%	92.23%
% of Gross Profit
Depreciation & Amortization	$900.0K	$700.0K	$600.0K
YoY Change	9.76%	16.67%	-29.41%
% of Gross Profit
Operating Expenses	$24.08M	$24.91M	$17.90M
YoY Change	47.96%	39.17%	1620.41%
Operating Profit	-$13.80M	-$17.12M	-$11.34M
YoY Change	52.49%	51.02%	88.02%
Interest Expense	$3.091M	$3.067M	$2.073M
YoY Change	16.68%	47.99%	-255.83%
% of Operating Profit
Other Income/Expense, Net	-$3.116M	-$3.054M	-$1.873M
YoY Change	30.5%	63.05%
Pretax Income	-$16.92M	-$20.18M	-$13.21M
YoY Change	47.9%	52.76%	-10.44%
Income Tax
% Of Pretax Income
Net Earnings	-$16.92M	-$20.18M	-$13.21M
YoY Change	47.9%	52.73%	-10.43%
Net Earnings / Revenue	-164.62%	-259.11%	-201.37%
Basic Earnings Per Share
Diluted Earnings Per Share	-$192.9K	-$233.7K	-$253.0K
COMMON SHARES
Basic Shares Outstanding	86.35M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q3	2020 Q2	2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$59.70M	$75.80M	$73.60M
YoY Change	24.38%	2.99%	33.33%
Cash & Equivalents	$59.68M	$75.78M	$73.62M
Short-Term Investments
Other Short-Term Assets	$3.800M	$4.700M	$1.600M
YoY Change	123.53%	193.75%	-33.33%
Inventory	$69.75M	$56.00M	$23.60M
Prepaid Expenses
Receivables	$6.335M	$6.514M	$5.100M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$139.5M	$143.0M	$103.9M
YoY Change	43.42%	37.62%	41.17%
LONG-TERM ASSETS
Property, Plant & Equipment	$39.62M	$37.37M	$29.40M
YoY Change	29.06%	27.12%	-2.97%
Goodwill	$3.530M	$3.530M
YoY Change
Intangibles	$2.623M	$2.802M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.900M	$4.800M	$2.800M
YoY Change	-32.14%	71.43%	-51.72%
Total Long-Term Assets	$50.43M	$48.55M	$39.40M
YoY Change	24.51%	23.23%	-10.86%
TOTAL ASSETS
Total Short-Term Assets	$139.5M	$143.0M	$103.9M
Total Long-Term Assets	$50.43M	$48.55M	$39.40M
Total Assets	$190.0M	$191.5M	$143.3M
YoY Change	37.86%	33.66%	21.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.980M	$6.910M	$6.800M
YoY Change	-11.34%	1.61%	119.35%
Accrued Expenses	$8.075M	$5.617M	$3.200M
YoY Change	61.5%	75.52%	-13.51%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$16.47M	$12.88M	$10.10M
YoY Change	8.38%	27.53%	46.38%
LONG-TERM LIABILITIES
Long-Term Debt	$97.00M	$96.60M	$82.40M
YoY Change	17.29%	17.23%	89.43%
Other Long-Term Liabilities	$67.81K	$80.73K	$3.900M
YoY Change	-98.22%	-97.93%	-75.0%
Total Long-Term Liabilities	$67.81K	$80.73K	$86.30M
YoY Change	-99.92%	-99.91%	46.02%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.47M	$12.88M	$10.10M
Total Long-Term Liabilities	$67.81K	$80.73K	$86.30M
Total Liabilities	$118.6M	$114.7M	$96.40M
YoY Change	16.62%	18.94%	46.06%
SHAREHOLDERS EQUITY
Retained Earnings	-$321.1M	-$304.1M
YoY Change
Common Stock	$8.962K	$8.635K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$71.38M	$76.88M	$46.91M
YoY Change
Total Liabilities & Shareholders Equity	$190.0M	$191.5M	$143.3M
YoY Change	37.86%	33.66%	21.65%

Cashflow Statement

Concept	2020 Q3	2020 Q2	2019 Q2
OPERATING ACTIVITIES
Net Income	-$16.92M	-$20.18M	-$13.21M
YoY Change	47.9%	52.73%	-10.43%
Depreciation, Depletion And Amortization	$900.0K	$700.0K	$600.0K
YoY Change	9.76%	16.67%	-29.41%
Cash From Operating Activities	-$23.85M	-$21.28M	-$18.62M
YoY Change	0.93%	14.29%	24.88%
INVESTING ACTIVITIES
Capital Expenditures	-$2.890M	-$4.170M	-$140.0K
YoY Change	46.7%	2878.57%	-72.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$2.890M	-$4.170M	-$140.0K
YoY Change	46.7%	2878.57%	-72.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$51.80M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.63M	0.000	75.84M
YoY Change	-106400.0%	-100.0%	76.66%
NET CHANGE
Cash From Operating Activities	-23.85M	-21.28M	-18.62M
Cash From Investing Activities	-2.890M	-4.170M	-140.0K
Cash From Financing Activities	10.63M	0.000	75.84M
Net Change In Cash	-16.11M	-25.45M	57.08M
YoY Change	-37.09%	-144.59%	107.41%
FREE CASH FLOW
Cash From Operating Activities	-$23.85M	-$21.28M	-$18.62M
Capital Expenditures	-$2.890M	-$4.170M	-$140.0K
Free Cash Flow	-$20.96M	-$17.11M	-$18.48M
YoY Change	-3.23%	-7.41%	28.24%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.49
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.53
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.96
CY2020Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	706919	USD
CY2020Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	603858	USD
CY2020Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	2205047	USD
CY2020Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	5198657	USD
CY2019Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	229073	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2533593	USD
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	12880029	USD
CY2020Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	86349981	shares
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	75781122	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26752135	USD
CY2020Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6514165	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3469919	USD
CY2020Q2	us-gaap	Inventory Net InventoryNet	56001348	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	53064734	USD
CY2020Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4693427	USD
CY2020Q2	us-gaap	Assets Current AssetsCurrent	142990062	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	85820381	USD
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	37373366	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31741317	USD
CY2020Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2801797	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3159474	USD
CY2020Q2	us-gaap	Goodwill Goodwill	3529509	USD
CY2019Q4	us-gaap	Goodwill Goodwill	3529509	USD
CY2020Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	4846834	USD
CY2019Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	2840044	USD
CY2020Q2	us-gaap	Assets Net AssetsNet	191541568	USD
CY2019Q4	us-gaap	Assets Net AssetsNet	127090725	USD
CY2020Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	6909659	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9174591	USD
CY2020Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5616666	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4481395	USD
CY2020Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	142834	USD
CY2019Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	142834	USD
CY2020Q2	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	210870	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14027893	USD
CY2020Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	81648187	USD
CY2019Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	68291163	USD
CY2020Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2190115	USD
CY2019Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2261532	USD
CY2020Q2	us-gaap	Subordinated Long Term Debt SubordinatedLongTermDebt	14925760	USD
CY2019Q4	us-gaap	Subordinated Long Term Debt SubordinatedLongTermDebt	14908053	USD
CY2020Q2	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	2937292	USD
CY2019Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	1302361	USD
CY2020Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	80730	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	106574	USD
CY2020Q2	us-gaap	Liabilities Liabilities	114662113	USD
CY2019Q4	us-gaap	Liabilities Liabilities	100897576	USD
CY2020Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	59318355	shares
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	86349981	shares
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	8635	USD
CY2020Q2	us-gaap	Cost Of Revenue CostOfRevenue	13495629	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	5932	USD
CY2020Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	381010696	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	290903772	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-304139876	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-264716555	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	76879455	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	26193149	USD
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	191541568	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	127090725	USD
CY2020Q2	adma	Product Revenue ProductRevenue	7751885	USD
CY2019Q2	adma	Product Revenue ProductRevenue	6525233	USD
	adma	Product Revenue ProductRevenue	17915921	USD
	adma	Product Revenue ProductRevenue	10018114	USD
CY2020Q2	adma	License Revenue LicenseRevenue	35709	USD
CY2019Q2	adma	License Revenue LicenseRevenue	35709	USD
	adma	License Revenue LicenseRevenue	71417	USD
	adma	License Revenue LicenseRevenue	71417	USD
CY2020Q2	us-gaap	Revenues Revenues	7787594	USD
CY2019Q2	us-gaap	Revenues Revenues	6560942	USD
	us-gaap	Revenues Revenues	17987338	USD
	us-gaap	Revenues Revenues	10089531	USD
CY2019Q2	us-gaap	Cost Of Revenue CostOfRevenue	10491236	USD
	us-gaap	Cost Of Revenue CostOfRevenue	30324855	USD
	us-gaap	Cost Of Revenue CostOfRevenue	19896415	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1656420	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	516986	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3185158	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1387621	USD
CY2020Q2	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	877902	USD
CY2019Q2	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	594113	USD
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	1378546	USD
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	1248599	USD
CY2020Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	178838	USD
CY2019Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	211234	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	357676	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	422469	USD
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8702630	USD
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6086047	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16634714	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11681517	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	24911419	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	17899616	USD
	us-gaap	Operating Expenses OperatingExpenses	51880949	USD
	us-gaap	Operating Expenses OperatingExpenses	34636621	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-17123825	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-11338674	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-33893611	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-24547090	USD
CY2020Q2	us-gaap	Interest Income Other InterestIncomeOther	19411	USD
CY2019Q2	us-gaap	Interest Income Other InterestIncomeOther	209808	USD
	us-gaap	Interest Income Other InterestIncomeOther	267479	USD
	us-gaap	Interest Income Other InterestIncomeOther	337207	USD
CY2020Q2	us-gaap	Interest Expense InterestExpense	3067306	USD
	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	0	USD
	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	11527421	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	874732	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	340481	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2019Q2	us-gaap	Interest Expense InterestExpense	2072578	USD
	us-gaap	Interest Expense InterestExpense	5784397	USD
	us-gaap	Interest Expense InterestExpense	3613085	USD
CY2020Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2019Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	9962495	USD
CY2020Q2	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	0	USD
CY2019Q2	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	0	USD
	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	0	USD
	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	11527421	USD
CY2020Q2	us-gaap	Other Income OtherIncome	-6371	USD
CY2019Q2	us-gaap	Other Income OtherIncome	-10428	USD
	us-gaap	Other Income OtherIncome	-12792	USD
	us-gaap	Other Income OtherIncome	-21785	USD
CY2020Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3054266	USD
CY2019Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1873198	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5529710	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1732737	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-20178091	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-13211872	USD
	us-gaap	Net Income Loss NetIncomeLoss	-39423321	USD
	us-gaap	Net Income Loss NetIncomeLoss	-26279827	USD
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	86347467	shares
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	52206204	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	80064641	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	49295805	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	26193149	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	676548	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	88704039	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7177	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-19245230	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	96335683	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	715608	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6255	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-20178091	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	76879455	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	19770438	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	637263	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	2699208	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-13067955	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	10038954	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	75048	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	48397088	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	879907	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	726736	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-13211872	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	46905861	USD
	us-gaap	Net Income Loss NetIncomeLoss	-39423321	USD
	us-gaap	Net Income Loss NetIncomeLoss	-26279827	USD
CY2019Q4	adma	Subordinated Debt Instrument Unamortized Discount SubordinatedDebtInstrumentUnamortizedDiscount	-91947	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1674490	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1611422	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	3518	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	8788	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1392156	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1363999	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7762763	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1	P10Y
CY2020Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3282227	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2801797	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6084024	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2924550	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3159474	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	357676	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	715352	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	715352	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	298065	USD
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	-30000000	USD
CY2020Q2	us-gaap	Depreciation Depreciation	700000	USD
	us-gaap	Depreciation Depreciation	1300000	USD
CY2019Q2	us-gaap	Depreciation Depreciation	600000	USD
	us-gaap	Depreciation Depreciation	1200000	USD
CY2020Q2	us-gaap	Notes Payable NotesPayable	85000000	USD
CY2019Q4	us-gaap	Notes Payable NotesPayable	72500000	USD
CY2020Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	-3351813	USD
CY2019Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	-4208837	USD
CY2019Q4	adma	Subordinated Debt Carrying Value SubordinatedDebtCarryingValue	15000000	USD
CY2020Q2	adma	Subordinated Debt Carrying Value SubordinatedDebtCarryingValue	15000000	USD
CY2020Q2	adma	Subordinated Debt Instrument Unamortized Discount SubordinatedDebtInstrumentUnamortizedDiscount	-74240	USD
	us-gaap	Payments For Fees PaymentsForFees	0	USD
	us-gaap	Payments For Fees PaymentsForFees	2760000	USD
	adma	Payment Of Debt Refinancing Fees PaymentOfDebtRefinancingFees	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	9962495	USD
	adma	Amortization Of License Revenue AmortizationOfLicenseRevenue	-71417	USD
	adma	Amortization Of License Revenue AmortizationOfLicenseRevenue	-71417	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3044246	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3694222	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2936614	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-5175148	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-2159834	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	163747	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-283195	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	118832	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2264932	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	887753	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	399295	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-529589	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-92067	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-91029	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-45931435	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-32911136	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-6243284	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-245675	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6241284	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-245675	USD
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	0	USD
	adma	Payment Of Debt Refinancing Fees PaymentOfDebtRefinancingFees	6499867	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	12500000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	72500000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1679661	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	88704039	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	48397088	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	13432	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	75048	USD
	us-gaap	Payments For Leasing Costs PaymentsForLeasingCosts	15765	USD
	us-gaap	Payments For Leasing Costs PaymentsForLeasingCosts	-14740	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	101201706	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	80017868	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	49028987	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	46861057	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26752135	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26754852	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	75781122	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	73615909	USD
CY2020Q2	adma	Working Capital WorkingCapital	130100000	USD
	us-gaap	Net Income Loss NetIncomeLoss	304100000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9265939	shares
	us-gaap	Use Of Estimates UseOfEstimates	<p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Use of estimates</span></em></p><p style="MARGIN: 0px; text-align:left;"> </p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the realizable value of accounts receivable, valuation of inventory, assumptions used in projecting future liquidity and capital requirements, assumptions used in the fair value of awards granted under the Company’s equity incentive plans and warrants issued in connection with the issuance of notes payable and the valuation allowance for the Company’s deferred tax assets.</p>
CY2020Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	24830796	USD
CY2019Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	33381806	USD
CY2020Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	22066417	USD
CY2019Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	14455665	USD
CY2020Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	9104135	USD
CY2019Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5227263	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6084024	USD
CY2020Q2	adma	Amortization Expense AmortizationExpense	200000	USD
	adma	Amortization Expense AmortizationExpense	400000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	715352	USD
CY2020Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	44411653	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	37466273	USD
CY2020Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7038287	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5724956	USD
	adma	Perceptive Tranche I Note And Perceptive Tranche Ii Fees Paid PerceptiveTrancheINoteAndPerceptiveTrancheIiFeesPaid	30000000.0	USD
	adma	Description Of Prepaid Principal Amount DescriptionOfPrepaidPrincipalAmount	(i) 5.0% of the prepaid principal amount, if prepaid on or prior to the first anniversary of the Perceptive Closing Date, (ii) 4.0% of the prepaid principal amount, if prepaid after the first anniversary of the Perceptive Closing Date and on or prior to the second anniversary of the Perceptive Closing Date, or (iii) 3.0% of the prepaid principal amount, if prepaid after the second anniversary of the Perceptive Closing Date and on or prior to the third anniversary of the Perceptive Closing Date.
CY2019Q2	adma	Perceptive Tranche I Note And Perceptive Tranche Ii Fees Paid PerceptiveTrancheINoteAndPerceptiveTrancheIiFeesPaid	5300000	USD
CY2019Q2	us-gaap	Debt Conversion Converted Instrument Rate DebtConversionConvertedInstrumentRate	1.41	pure
CY2020Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86349981	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	59318355	shares
CY2020Q2	adma	Common Stock Reserved For Outstanding CommonStockReservedForOutstanding	9265939	shares
CY2020Q2	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	54384080	shares
CY2020Q1	adma	Underwritten Public Offering UnderwrittenPublicOffering	23500000	shares
CY2020Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	82300000	USD
CY2020Q1	adma	Underwritten Public Offering UnderwrittenPublicOffering	3525000	shares
CY2020Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	12300000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	88700000	USD
CY2020Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2138160	shares
CY2020Q2	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	3.81
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5630351	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.76
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	-47683	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.51
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	-6763	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	4.34
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1232500	shares
	adma	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriod	-6626	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.03
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6801779	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.45
	adma	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod	4030098	shares
	adma	Share Based Compensation Arrangement By Share Based Payment Award Option Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageExercisePrice	5.19
CY2020Q2	us-gaap	Share Based Compensation ShareBasedCompensation	715608	USD
CY2019Q2	us-gaap	Share Based Compensation ShareBasedCompensation	726736	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1392156	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1363999	USD
CY2020Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	721005	USD
CY2020Q2	adma	Operating Lease Liability Total OperatingLeaseLiabilityTotal	2937292	USD
	adma	Credit Facility Percentage CreditFacilityPercentage	10	pure
	adma	Public Offering Description PublicOfferingDescription	(i) Perceptive Advisors, a principal stockholder of ADMA, purchased 4,563,700 shares of common stock through one of its affiliates, (ii) Dr. Grossman purchased 22,857 shares of common stock directly and 22,857 shares indirectly through an entity he controls (iii) Lawrence P. Guiheen, a director of the Company, purchased 20,000 shares of common stock, (iv) Mr. Grossman purchased 28,571 shares of common stock directly and 57,143 shares indirectly through an entity he controls (v) Brian Lenz, the Company’s Executive Vice President and Chief Financial Officer, purchased 7,142 shares of common stock, and (vi) James Mond, the Company’s Chief Scientific Officer and Chief Medical Officer, purchased 4,285 shares of common stock, all at the public offering price of $3.50 per share.
	adma	Plasma Supply Agreement Term PlasmaSupplyAgreementTerm	P10Y
	adma	Purchase Of Raw Material PurchaseOfRawMaterial	3700000	USD
	adma	Purchase Percentage From Inventory PurchasePercentageFromInventory	42	pure
	adma	Purchase Of Raw Material PurchaseOfRawMaterial	5000000.0	USD
	adma	Purchase Percentage From Inventory PurchasePercentageFromInventory	67	pure
CY2020Q2	us-gaap	Business Combination Assets And Liabilities Arising From Contingencies Amount Recognized BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized	12600000	USD
CY2019Q1	adma	Gain Upon Transfer Facilities GainUponTransferFacilities	11500000	USD
CY2019Q1	adma	Net Carrying Value Of Assets NetCarryingValueOfAssets	1100000	USD
	adma	Incremental Borrowing Rate IncrementalBorrowingRate	13	pure
CY2020Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	100000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1700000	USD
CY2020Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	3100000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1500000	USD
CY2020Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y4M24D
CY2020Q2	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	262076	USD
CY2020Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	699752	USD
CY2020Q2	adma	Interest Portion Of Minimum Lease Payments InterestPortionOfMinimumLeasePayments	-2050495	USD
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	-210870	USD
CY2020Q3	adma	Lease Description LeaseDescription	With the exception of advance deposits and initial months’ rent totaling approximately $74,000, no payments have been made under these leases. The initial terms of each lease are from 11 to 13 years with monthly rental payments varying between approximately $17,000 and $21,000, including common area maintenance charges.
	us-gaap	Interest Paid Net InterestPaidNet	4912165	USD
	us-gaap	Interest Paid Net InterestPaidNet	3574304	USD
	adma	Equipment Acquired Reflected In Accounts Payable And Accrued Liabilities EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities	1228000	USD
	adma	Equipment Acquired Reflected In Accounts Payable And Accrued Liabilities EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities	290389	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1723594	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1421669	USD
	adma	Warrants Issued In Connection With Note Payable WarrantsIssuedInConnectionWithNotePayable	0	USD
	adma	Warrants Issued In Connection With Note Payable WarrantsIssuedInConnectionWithNotePayable	3579115	USD

Files In Submission

Name	View Source	Status
0001193805-20-000960-index-headers.html	Edgar Link	pending
0001193805-20-000960-index.html	Edgar Link	pending
0001193805-20-000960.txt	Edgar Link	pending
0001193805-20-000960-xbrl.zip	Edgar Link	pending
adma-20200630.xsd	Edgar Link	pending
adma-20200630_cal.xml	Edgar Link	unprocessable
adma-20200630_def.xml	Edgar Link	unprocessable
adma-20200630_lab.xml	Edgar Link	unprocessable
adma-20200630_pre.xml	Edgar Link	unprocessable
adma_10q.htm	Edgar Link	pending
adma_10q_htm.xml	Edgar Link	completed
adma_ex11.htm	Edgar Link	pending
adma_ex311.htm	Edgar Link	pending
adma_ex312.htm	Edgar Link	pending
adma_ex321.htm	Edgar Link	pending
adma_ex322.htm	Edgar Link	pending
adma_ex51.htm	Edgar Link	pending
adma_ex51img2.jpg	Edgar Link	pending
adma_ex51img5.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ADMA
ADMA BIOLOGICS, INC. Stock $adma

2020 Q3 Form 10-Q Financial Statement

#000119380520000960 Filed on August 05, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADMA ADMA BIOLOGICS, INC. Stock $adma

2020 Q3 Form 10-Q Financial Statement

#000119380520000960 Filed on August 05, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADMA
ADMA BIOLOGICS, INC. Stock $adma